secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2022-03-23T23:59:59+00:00
Accession:  0001104659-22-037034
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharmaceuticals appoints Renee P. Tannenbaum to Board of Directors
----------------------------------------------------------------------

- Board expanded from 8 to 9 members; Dr. Tannenbaum appointed effective March 19, 2022.
- Received initial restricted stock award with $435,000 grant date fair value, vesting over 3 years.
- Dr. Tannenbaum brings over 35 years pharma experience; previously at Halozyme, AbbVie, Novartis, BMS, Merck.
- Appointment supports commercialization of Purified Cortrophin Gel, according to board chair.
- Dr. Tannenbaum determined independent under Nasdaq rules; no committee assignment yet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000110465922037034/0001104659-22-037034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000110465922037034/tm2210247d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-037034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer